In NSCLC, durvalumab’s greatest impact is seen in unresectable stage III disease following chemoradiotherapy; however, its efficacy diminishes in patients with low or absent PD-L1 expression [246,280]. Here, CD274 is linked to non-small cell lung carcinoma.